Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.57
AZN's Cash to Debt is ranked higher than
56% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. AZN: 0.57 )
AZN' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.57

Equity to Asset 0.38
AZN's Equity to Asset is ranked higher than
51% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. AZN: 0.38 )
AZN' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.59
Current: 0.38

0.3
0.59
Interest Coverage 7.50
AZN's Interest Coverage is ranked higher than
52% of the 449 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. AZN: 7.50 )
AZN' s 10-Year Interest Coverage Range
Min: 6.85   Max: 158.12
Current: 7.5

6.85
158.12
F-Score: 4
Z-Score: 2.48
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.44
AZN's Operating margin (%) is ranked higher than
82% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. AZN: 14.44 )
AZN' s 10-Year Operating margin (%) Range
Min: 1.47   Max: 38.09
Current: 14.44

1.47
38.09
Net-margin (%) 9.94
AZN's Net-margin (%) is ranked higher than
78% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. AZN: 9.94 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.42   Max: 29.72
Current: 9.94

6.42
29.72
ROE (%) 11.01
AZN's ROE (%) is ranked higher than
83% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. AZN: 11.01 )
AZN' s 10-Year ROE (%) Range
Min: 11.01   Max: 42.95
Current: 11.01

11.01
42.95
ROA (%) 4.57
AZN's ROA (%) is ranked higher than
74% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.09 vs. AZN: 4.57 )
AZN' s 10-Year ROA (%) Range
Min: 4.57   Max: 20.19
Current: 4.57

4.57
20.19
ROC (Joel Greenblatt) (%) 63.80
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.47 vs. AZN: 63.80 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 3.24   Max: 199.14
Current: 63.8

3.24
199.14
Revenue Growth (%) -5.10
AZN's Revenue Growth (%) is ranked higher than
55% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. AZN: -5.10 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -57.6   Max: 28
Current: -5.1

-57.6
28
EBITDA Growth (%) -14.50
AZN's EBITDA Growth (%) is ranked higher than
56% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. AZN: -14.50 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -52.8   Max: 37.9
Current: -14.5

-52.8
37.9
EPS Growth (%) -29.50
AZN's EPS Growth (%) is ranked higher than
55% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -29.50 )
AZN' s 10-Year EPS Growth (%) Range
Min: -29.5   Max: 28.2
Current: -29.5

-29.5
28.2
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AZN Guru Trades in Q3 2013

Steven Cohen 532,113 sh (+4346.87%)
Pioneer Investments 590,122 sh (+23.7%)
Charles Brandes 2,381,040 sh (+7.92%)
David Dreman 179,261 sh (+4.4%)
Murray Stahl 12,020 sh (+0.17%)
NWQ Managers 85,850 sh (unchged)
Manning & Napier Advisors, Inc 508,945 sh (-0.53%)
HOTCHKIS & WILEY 4,912,449 sh (-0.65%)
Jim Simons 2,913,800 sh (-14.94%)
John Hussman 68,000 sh (-81.87%)
» More
Q4 2013

AZN Guru Trades in Q4 2013

Francis Chou 13,000 sh (New)
Stanley Druckenmiller 360,500 sh (New)
Pioneer Investments 651,839 sh (+10.46%)
Charles Brandes 2,503,848 sh (+5.16%)
Steven Cohen 533,262 sh (+0.22%)
Murray Stahl 12,020 sh (unchged)
NWQ Managers 85,450 sh (-0.47%)
Manning & Napier Advisors, Inc 490,878 sh (-3.55%)
Jim Simons 2,715,400 sh (-6.81%)
HOTCHKIS & WILEY 3,689,214 sh (-24.9%)
David Dreman 106,975 sh (-40.32%)
John Hussman 28,000 sh (-58.82%)
» More
Q1 2014

AZN Guru Trades in Q1 2014

Joel Greenblatt 95,518 sh (New)
John Hussman 228,000 sh (+714.29%)
David Dreman 135,439 sh (+26.61%)
Murray Stahl 13,106 sh (+9.03%)
Francis Chou 13,000 sh (unchged)
NWQ Managers 85,450 sh (unchged)
Stanley Druckenmiller 360,500 sh (unchged)
HOTCHKIS & WILEY Sold Out
Manning & Napier Advisors, Inc 459,569 sh (-6.38%)
Pioneer Investments 459,298 sh (-29.54%)
Steven Cohen 367,034 sh (-31.17%)
Charles Brandes 1,333,894 sh (-46.73%)
Jim Simons 1,429,000 sh (-47.37%)
» More
Q2 2014

AZN Guru Trades in Q2 2014

Paul Tudor Jones 27,100 sh (New)
Jeremy Grantham 28,000 sh (New)
Louis Moore Bacon 40,000 sh (New)
Mario Gabelli 40,400 sh (New)
George Soros 150,000 sh (New)
Jim Simons 1,794,800 sh (+25.6%)
Francis Chou 13,000 sh (unchged)
Daniel Loeb 1,000,000 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-06-30 Reduce -71.06%0.78%$62.45 - $81.09 $ 73.191%386058
Joel Greenblatt 2014-06-30 Sold Out 0.09%$62.45 - $81.09 $ 73.191%0
George Soros 2014-06-30 New Buy0.08%$62.45 - $81.09 $ 73.191%150000
Mario Gabelli 2014-06-30 New Buy0.02%$62.45 - $81.09 $ 73.191%40400
John Hussman 2014-03-31 Add 714.29%0.96%$58.51 - $68.15 $ 73.1914%228000
Charles Brandes 2014-03-31 Reduce -46.73%0.84%$58.51 - $68.15 $ 73.1914%1333894
David Dreman 2014-03-31 Add 26.61%0.14%$58.51 - $68.38 $ 73.1914%135439
Joel Greenblatt 2014-03-31 New Buy0.09%$58.51 - $68.38 $ 73.1914%95518
David Dreman 2013-12-31 Reduce -40.32%0.34%$49.72 - $59.5 $ 73.1935%106975
John Hussman 2013-12-31 Reduce -58.82%0.11%$49.72 - $59.5 $ 73.1935%28000
John Hussman 2013-09-30 Reduce -81.87%0.66%$47.88 - $52.08 $ 73.1946%68000
Charles Brandes 2013-09-30 Add 7.92%0.12%$47.88 - $52.08 $ 73.1946%2381040
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 45.50
AZN's P/E(ttm) is ranked higher than
68% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.60 vs. AZN: 45.50 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.07   Max: 46.6
Current: 45.5

6.07
46.6
P/B 4.30
AZN's P/B is ranked higher than
57% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.42 vs. AZN: 4.30 )
AZN' s 10-Year P/B Range
Min: 2.31   Max: 7.02
Current: 4.3

2.31
7.02
P/S 3.60
AZN's P/S is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.45 vs. AZN: 3.60 )
AZN' s 10-Year P/S Range
Min: 1.6   Max: 4.25
Current: 3.6

1.6
4.25
PFCF 24.50
AZN's PFCF is ranked higher than
85% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 24.50 )
AZN' s 10-Year PFCF Range
Min: 6.67   Max: 37.12
Current: 24.5

6.67
37.12
EV-to-EBIT 31.14
AZN's EV-to-EBIT is ranked higher than
75% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. AZN: 31.14 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 142.6
Current: 31.14

4.5
142.6
Shiller P/E 13.90
AZN's Shiller P/E is ranked higher than
95% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 13.90 )
AZN' s 10-Year Shiller P/E Range
Min: 8.05   Max: 27.94
Current: 13.9

8.05
27.94
Current Ratio 0.99
AZN's Current Ratio is ranked lower than
56% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. AZN: 0.99 )
AZN' s 10-Year Current Ratio Range
Min: 0.64   Max: 2.03
Current: 0.99

0.64
2.03
Quick Ratio 0.85
AZN's Quick Ratio is ranked lower than
53% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. AZN: 0.85 )
AZN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 2.03
Current: 0.85

0.54
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.80
AZN's Dividend Yield is ranked higher than
95% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. AZN: 3.80 )
AZN' s 10-Year Dividend Yield Range
Min: 1.51   Max: 6.75
Current: 3.8

1.51
6.75
Dividend Payout 1.74
AZN's Dividend Payout is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 1.74 )
AZN' s 10-Year Dividend Payout Range
Min: 0.24   Max: 4.87
Current: 1.74

0.24
4.87
Dividend growth (3y) 3.20
AZN's Dividend growth (3y) is ranked higher than
79% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.10 vs. AZN: 3.20 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -6.3   Max: 30.1
Current: 3.2

-6.3
30.1
Yield on cost (5-Year) 5.52
AZN's Yield on cost (5-Year) is ranked higher than
95% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. AZN: 5.52 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.14   Max: 9.56
Current: 5.52

2.14
9.56
Share Buyback Rate 4.60
AZN's Share Buyback Rate is ranked higher than
92% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. AZN: 4.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -144.8
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.18
AZN's Price/DCF (Projected) is ranked higher than
98% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.80 vs. AZN: 1.18 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 5.14
Current: 1.18

0.5
5.14
Price/Median PS Value 1.48
AZN's Price/Median PS Value is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. AZN: 1.48 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.47
Current: 1.48

0.69
2.47
Earnings Yield (Greenblatt) 3.20
AZN's Earnings Yield (Greenblatt) is ranked higher than
58% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. AZN: 3.20 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 22.2
Current: 3.2

0.7
22.2
Forward Rate of Return (Yacktman) -4.31
AZN's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. AZN: -4.31 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.9   Max: 34.8
Current: -4.31

-5.9
34.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA
AstraZeneca PLC is engaged in the global, prescription-based biopharmaceutical business. Its pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. It focuses on six therapy areas of healthcare such as Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation. The Company has operations in the United Kingdom, Continental Europe, The Americas, Asia, Africa, and Australia.
» More Articles for NYSE:AZN

Headlines

Articles On GuruFocus.com
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
10 British Stocks to Consider Feb 20 2014 
Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


More From Other Websites
Take Advantage Of The ‘Summer Dip’ With The FTSE 100, AstraZeneca plc & Vodafone Group plc Aug 22 2014
GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA Aug 21 2014
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data Aug 21 2014
Illumina Partners with AstraZeneca, Sanofi, Janssen in NGS Aug 21 2014
Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Aug 21 2014
Raiffeisen rallies, miners slip: Europe movers Aug 21 2014
Video: Illumina Partners With Big Pharma Firms Aug 21 2014
Healthcare stocks lift UK's FTSE 100 Aug 21 2014
Healthcare stocks lift UK's FTSE 100 Aug 21 2014
Why AstraZeneca (AZN) Stock Is Higher Today Aug 21 2014
Healthcare stocks lift UK's FTSE 100 Aug 21 2014
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for... Aug 21 2014
Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer Aug 21 2014
The Risks Of Investing In AstraZeneca plc Aug 21 2014
Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease Aug 20 2014
Ampio's Ampion Positive in Open Label Study, Shares Up Aug 20 2014
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study Aug 20 2014
AstraZeneca and Mitsubishi Tanabe link on diabetes research Aug 20 2014
US Department Of Justice Ends Investigation Of AstraZeneca Trial Aug 19 2014
Will Roche (RHHBY) Buy the Remaining Stake in Chugai? Aug 19 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide